Suppr超能文献

重氮乙酰甘氨酸乙酯-蛙皮素的优化生产:靶向胃泌素释放肽受体的新型治疗剂

Optimized Production of Re-HYNIC-Bombesin: New Therapeutic Agent for GRPR Targeting.

作者信息

Vosoughi Sara, Salek Nafise, Zolghadri Samaneh, Aghamiri Seyed Mahmoud Reza, Delavari Milad

机构信息

Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Box 14395‑836, North Kargar Street, Tehran, Iran.

Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI), Box 14395‑836, North Kargar Street, Tehran, Iran.

出版信息

Nucl Med Mol Imaging. 2024 Aug;58(5):300-309. doi: 10.1007/s13139-024-00866-1. Epub 2024 Jun 1.

Abstract

PURPOSE

One of the most interesting methods to deliver therapeutic doses of ionizing radiation to tumor sites is radiolabeled compounds. Bombesin peptide binds to gastrin-releasing peptide receptors (GRPRs) with great affinity. Through its appropriate physical characteristics and accessibility as the W/Re generator, Re can be effectively used to develop a therapeutic radio complex. In this study, Re-HYNIC-BBN was prepared under optimal conditions.

METHODS

Optimization of the effective parameters on Re-HYNIC-BBN radio-labeling yield like ligand concentration, pH, reaction time, and temperature were performed. The final product's radiochemical purity was measured by RTLC and HPLC. The stability of the radio-complex was checked in PBS buffer (4 °C) and human blood serum (37 °C). The partition coefficient of the final radio-complex was studied using standard procedure. Finally, the biodistribution of Re-HYNIC-BBN and free Re in different organs of the rats were compared in various intervals.

RESULTS

The final product was prepared with a specific activity of 7.11 TBq/mmol and radiochemical purity > 95% at the optimized conditions (pH = 4-5, reaction time = 45 min, temp = 95℃). This radio-complex was found to be stable in PBS and blood serum over 24 h. LogP was - 1.78, showing the high hydrophilic nature of the radio-complex. The biodistribution of Re-HYNIC-BBN demonstrated the fast clearance of the radio-peptide from the blood circulation. The most portion of the radioactivity was excreted from the body via the urinary tract and the remaining activity was accumulated in GRPR-expressing organs.

CONCLUSION

The special characteristics of the complex introduce Re-HYNIC-BBN as a new therapeutic agent for targeting GRPRs, however, more biological data is still needed.

摘要

目的

将治疗剂量的电离辐射输送到肿瘤部位的最有趣方法之一是放射性标记化合物。蛙皮素肽与胃泌素释放肽受体(GRPRs)具有很高的亲和力。通过其作为W/Re发生器的适当物理特性和可及性,Re可有效地用于开发治疗性放射性复合物。在本研究中,在最佳条件下制备了Re-HYNIC-BBN。

方法

对Re-HYNIC-BBN放射性标记产率的有效参数进行优化,如配体浓度、pH值、反应时间和温度。通过RTLC和HPLC测量最终产物的放射化学纯度。在PBS缓冲液(4℃)和人血清(37℃)中检查放射性复合物的稳定性。使用标准程序研究最终放射性复合物的分配系数。最后,在不同时间间隔比较Re-HYNIC-BBN和游离Re在大鼠不同器官中的生物分布。

结果

在优化条件(pH = 4-5,反应时间 = 45分钟,温度 = 95℃)下制备的最终产物的比活度为7.11 TBq/mmol,放射化学纯度>95%。发现该放射性复合物在PBS和血清中24小时内稳定。LogP为-1.78,表明该放射性复合物具有高亲水性。Re-HYNIC-BBN的生物分布表明放射性肽从血液循环中快速清除。大部分放射性通过尿路排出体外,其余活性积聚在表达GRPR的器官中。

结论

该复合物的特殊特性使Re-HYNIC-BBN成为一种靶向GRPRs的新型治疗剂,然而,仍需要更多的生物学数据。

相似文献

5
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.

本文引用的文献

2
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
5
Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症:临床进展与挑战。
Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
8
Update on radionuclide therapy in oncology.肿瘤学中放射性核素治疗的最新进展。
Oncol Lett. 2017 Dec;14(6):7011-7015. doi: 10.3892/ol.2017.7141. Epub 2017 Oct 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验